Research Reports Coverage on Farm & Construction Machinery Stocks -- Terex, AGCO, Cascadian Therapeutics, and Titan Intl.

Sep 16, 2016, 07:50 ET from Chelmsford Park SA

NEW YORK, September 16, 2016 /PRNewswire/ -- is currently looking at the Farm and Construction Machinery space, which recorded a 12.4% decline in shipments in the first half of 2016, as per the U.S. Census Bureau. Let us assess the most recent performances of the following equities and see where they stand in the market right now: Terex Corp. (NYSE: TEX), AGCO Corp. (NYSE: AGCO), Cascadian Therapeutics Inc. (NASDAQ: CASC), and Titan International Inc. (NYSE: TWI). These stocks research reports can be downloaded now by simply registering for free at:


On Thursday, shares in Westport, Connecticut-based Terex Corp. recorded a trading volume of 796,509 shares. The stock ended the session 4.06% higher at $24.35. The Company's shares have gained 1.08% in the last one month, 16.17% in the previous three months, and 33.00% on an YTD basis. The stock is trading 4.88% above its 50-day moving average and 11.44% above its 200-day moving average. Moreover, shares of Terex, which operates as a lifting and material handling solutions company, have a Relative Strength Index (RSI) of 54.68.

On August 8th, 2016, Terex announced that the proposed transactions for the sale of Terex's Material Handling & Port Solutions business to Konecranes have received European Commission approval. The approval is conditioned on a commitment by Konecranes to divest their Stahl CraneSystems business. Konecranes has announced that it will begin this divestiture process immediately.

On September 7th, 2016, research firm Deutsche Bank initiated a 'Hold' rating on the Company's stock, issuing a target price of $26 per share. Your complete research report on TEX can be retrieved for free at:

AGCO Corp. 

Duluth, Georgia headquartered AGCO Corp.'s stock closed the day 1.40% higher at $47.11, with a total trading volume of 425,368 shares. The Company's shares have advanced 4.63% since the start of this year. The stock is trading 2.06% below its 50-day moving average. Additionally, shares of AGCO Corp., which manufactures and distributes agricultural equipment and related replacement parts worldwide, have an RSI of 44.85.

On August 30th, 2016, AGCO announced feature upgrades for its AgCommand® telemetry product and Fuse® Connected Services offering. The new features will allow growers to optimize their farming operations through broader connectivity and improved support and diagnostics. AGCO will be adding enhanced remote support capabilities, which will enable dealers and customers to more quickly identify and resolve machine and operational issues in near real-time, reducing downtime in the field.

On September 7th, 2016, research firm Deutsche Bank initiated a 'Hold' rating on the Company's stock, issuing a target price of $54 per share. AGCO free report is just a click away at:

Cascadian Therapeutics  

Shares in Seattle, Washington headquartered Cascadian Therapeutics Inc. recorded a trading volume of 989,665 shares, which was higher than their three months average volume of 754,610 shares. The stock ended yesterday's trading session 3.33% higher at $1.24. The Company's shares have advanced 6.90% in the past month and 26.53% over the previous three months. The stock is trading above its 50-day moving average by 10.30%. Furthermore, shares of Cascadian Therapeutics, which engages in the research and development of therapeutic products for the treatment of cancer, have an RSI of 64.80.

On August 31st, 2016, Cascadian Therapeutics announced that the United States Adopted Names (USAN) Council and the International Nonproprietary Names (INN) Expert Group have approved the nonproprietary name "tucatinib" for ONT-380, the company's lead product candidate for the treatment of advanced, metastatic HER2+ breast cancer. Scott Myers, President and CEO of Cascadian Therapeutics said: "Tucatinib has shown promising systemic activity, encouraging activity against brain metastases, and a favorable safety profile in patients with advanced HER2+ breast cancer. We continue to enroll our Phase 2 combination trial, HER2CLIMB, and plan to report new data from our ongoing Phase 1b 'Triplet' study of tucatinib in combination with capecitabine and trastuzumab later this year." Sign up for your complimentary research report on CASC at:

Titan Intl. 

Quincy, Illinois-based Titan International Inc.'s stock finished Thursday's session 1.72% higher at $8.88, with a total trading volume of 328,114 shares. The Company's shares have surged 36.10% over the previous three months and 125.78% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 9.80% and 53.08%, respectively. Additionally, shares of Titan International, which together with its subsidiaries, manufactures and sells wheels, tires, wheel and tire assemblies, and undercarriage systems and components for off-highway vehicles in the US and internationally, have an RSI of 50.33.

On September 9th, 2016, the Board of Directors of Titan International approved a quarterly cash dividend of $.005 per common share for Q3 2016. The cash dividend is payable on October 14th, 2016, to stockholders of record on September 30th, 2016. Register for free on and download the latest research report on TWI at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number:  +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA